Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C34H41N3O7.2C6H8O7 |
Molecular Weight | 987.9523 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 1 / 1 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
OC(=O)CC(O)(CC(O)=O)C(O)=O.OC(=O)CC(O)(CC(O)=O)C(O)=O.COC1=CC(=CC(OC)=C1OC)C(=O)C(=O)N2CCCC[C@H]2C(=O)OC(CCCC3=CC=CN=C3)CCCC4=CC=CN=C4
InChI
InChIKey=VDMKJSJJXQDICL-ZXVJYWQYSA-N
InChI=1S/C34H41N3O7.2C6H8O7/c1-41-29-20-26(21-30(42-2)32(29)43-3)31(38)33(39)37-19-5-4-16-28(37)34(40)44-27(14-6-10-24-12-8-17-35-22-24)15-7-11-25-13-9-18-36-23-25;2*7-3(8)1-6(13,5(11)12)2-4(9)10/h8-9,12-13,17-18,20-23,27-28H,4-7,10-11,14-16,19H2,1-3H3;2*13H,1-2H2,(H,7,8)(H,9,10)(H,11,12)/t28-;;/m0../s1
Biricodar (also known as VX-710) was developed by Vertex as a chemosensitizing agent designed to restore the effectiveness of chemotherapeutic agents in tumor multidrug resistance. The phase II trials had commenced for biricodar, in combination with chemotherapy, for five common cancer indications: breast, ovarian, soft-tissue sarcomas, small cell lung cancer, and prostate cancer. In spite of completed trials, development of biricodar was discontinued because of the adverse effects.
Originator
Approval Year
PubMed
Title | Date | PubMed |
---|---|---|
Safety and efficacy of the multidrug-resistance inhibitor biricodar (VX-710) with concurrent doxorubicin in patients with anthracycline-resistant advanced soft tissue sarcoma. | 2002 Feb |
|
A phase II study of the MDR inhibitor biricodar (INCEL, VX-710) and paclitaxel in women with advanced ovarian cancer refractory to paclitaxel therapy. | 2002 Sep |
|
Overcoming multidrug resistance in cancer: an update on the clinical strategy of inhibiting p-glycoprotein. | 2003 Mar-Apr |
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/17285598
Patients received 80 mg/m(2) paclitaxel over 3 h starting 4 h after initiation of a 24-h continuous intravenous infusion of 120 mg/m(2)/h biricodar (VX-710). Cycles were repeated every 3 weeks.
Route of Administration:
Intravenous
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Brand Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NCI_THESAURUS |
C1744
Created by
admin on Fri Dec 15 15:57:17 GMT 2023 , Edited by admin on Fri Dec 15 15:57:17 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
9WQP0L619L
Created by
admin on Fri Dec 15 15:57:17 GMT 2023 , Edited by admin on Fri Dec 15 15:57:17 GMT 2023
|
PRIMARY | |||
|
C1653
Created by
admin on Fri Dec 15 15:57:17 GMT 2023 , Edited by admin on Fri Dec 15 15:57:17 GMT 2023
|
PRIMARY | |||
|
174254-13-8
Created by
admin on Fri Dec 15 15:57:17 GMT 2023 , Edited by admin on Fri Dec 15 15:57:17 GMT 2023
|
PRIMARY | |||
|
CHEMBL350775
Created by
admin on Fri Dec 15 15:57:17 GMT 2023 , Edited by admin on Fri Dec 15 15:57:17 GMT 2023
|
PRIMARY | |||
|
DBSALT002850
Created by
admin on Fri Dec 15 15:57:17 GMT 2023 , Edited by admin on Fri Dec 15 15:57:17 GMT 2023
|
PRIMARY | |||
|
m2514
Created by
admin on Fri Dec 15 15:57:17 GMT 2023 , Edited by admin on Fri Dec 15 15:57:17 GMT 2023
|
PRIMARY | Merck Index | ||
|
II-62
Created by
admin on Fri Dec 15 15:57:17 GMT 2023 , Edited by admin on Fri Dec 15 15:57:17 GMT 2023
|
PRIMARY | |||
|
DTXSID30938483
Created by
admin on Fri Dec 15 15:57:17 GMT 2023 , Edited by admin on Fri Dec 15 15:57:17 GMT 2023
|
PRIMARY | |||
|
9963148
Created by
admin on Fri Dec 15 15:57:17 GMT 2023 , Edited by admin on Fri Dec 15 15:57:17 GMT 2023
|
PRIMARY |
ACTIVE MOIETY
PARENT (SALT/SOLVATE)
SUBSTANCE RECORD